Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSX-049
- Development stage
- Unknown
- Lead developer
- TesoRx Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TSX-049 is a novel, oral formulation of testosterone undecanoate (TU) developed by TesoRx Pharma for the treatment of hypogonadism in males. The drug utilizes TesoRx's proprietary proliposomal delivery platform, which is designed to enhance the bioavailability of testosterone and provide a dose response sufficient to overcome negative feedback of gonadal testosterone production. As an androgen receptor agonist, TSX-049 acts as a testosterone replacement therapy to restore physiological testosterone levels. This small molecule therapeutic aims to offer improved safety and convenience compared to traditional topical gels or injectable treatments. It has been evaluated in Phase 1/2 clinical trials.
- Other names
- testosterone undecanoateoral testosterone undecanoate
02
Targets
Beyond the preview
Go deeper on TSX-049.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSX-049.